The shares of Stemline Therapeutics Inc. (NASDAQ:STML) has been pegged with a rating of Buy by H.C. Wainwright in its latest research note that was published on January 21, 2020. The Healthcare company has also assigned a $20 price target. H.C. Wainwright wasn’t the only research firm that published a report of Stemline Therapeutics Inc., with other equities research analysts also giving their opinion on the stock. Cantor Fitzgerald advised investors in its research note published on December 24, 2019, to Overweight the STML stock while also putting a $18 price target. The stock had earned Buy rating from Alliance Global Partners Markets when it published its report on November 25, 2019. That day the Alliance Global Partners set price target on the stock to $21. Wedbush was of a view that STML is Neutral in its latest report on May 13, 2019. JP Morgan thinks that STML is worth Overweight rating. This was contained in the firm’s report on December 11, 2018 in which the stock’s price target was also moved to 17.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 0 believe it has the potential for further growth, thus rating it as Hold while 9 advised investors to purchase the stock. The consensus currently stands at a Buy while its average price target is $17.56. The price of the stock the last time has raised by 32.09% from its 52-Week high price while it is -76.73% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 39.60.
The shares of the company dipped by -4.29% during the trading session on Wednesday, reaching a low of $4.20 while ending the day at $4.24. During the trading session, a total of 647220.0 shares were traded which represents a 30.81% incline from the average session volume which is 935420.0 shares. STML had ended its last session trading at $4.43. Stemline Therapeutics Inc. debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 8.00 STML 52-week low price stands at $3.21 while its 52-week high price is $18.22.
The company in its last quarterly report recorded -$0.38 earnings per share which is above the predicted by most analysts. The Stemline Therapeutics Inc. generated 13.56 million in revenue during the last quarter. In the second quarter last year, the firm recorded -$0.34 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -92.11%. Stemline Therapeutics Inc. has the potential to record -1.29 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Citigroup published a research note on February 19, 2020 where it informed investors and clients that Stanley Black & Decker Inc. (NYSE:SWK) is now rated as Buy. Their price target on the stock stands at $205. UBS also rated SWK as Initiated on December 12, 2019, with its price target of $200 suggesting that SWK could surge by 41.37% from its current share price. Even though the stock has been trading at $90.27/share, analysts expect it to surge by 8.85% to reach $167.60/share. It started the day trading at $105.43 and traded between $90.705 and $98.26 throughout the trading session.
A look at its technical shows that SWK’s 50-day SMA is 142.45 while its 200-day SMA stands at 147.02. The stock has a high of $173.67 for the year while the low is $70.00. The stock, however, witnessed a rise in its short on 03/13/20. Compared to previous close which recorded 4.2 M shorted shares, the short percentage went higher by 16.53%, as 4.89M STML shares were shorted. At the moment, only 2.92% of Stanley Black & Decker Inc. shares were sold short. The company’s P/E ratio currently sits at 15.43, while the P/B ratio is 1.92. The company’s average trading volume currently stands at 1.70M shares, which means that the short-interest ratio is just 2.47 days. Over the past seven days, the company moved, with its shift of 25.44%. Looking further, the stock has dropped -41.05% over the past 90 days while it lost -28.95% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The The Vanguard Group, Inc. bought more SWK shares, increasing its portfolio by 0.86% during the last quarter. This move now sees The The Vanguard Group, Inc. purchasing 106,683 shares in the last quarter, thus it now holds 12,472,638 shares of SWK, with a total valuation of $1,792,318,081. Massachusetts Financial Services … meanwhile sold more SWK shares in the recently filed quarter, changing its stake to $1,074,062,514 worth of shares.
Similarly, SSgA Funds Management, Inc. increased its Stanley Black & Decker Inc. shares by 1.81% during the recently filed quarter. After buying 7,208,575 shares in the last quarter, the firm now controls 128,042 shares of Stanley Black & Decker Inc. which are valued at $1,035,872,228. In the same vein, BlackRock Fund Advisors increased its Stanley Black & Decker Inc. shares by during the most recent reported quarter. The firm bought 115,429 shares during the quarter which increased its stakes to 7,090,468 shares and is now valued at $1,018,900,252. Following these latest developments, around 0.30% of Stanley Black & Decker Inc. stocks are owned by institutional investors and hedge funds.